Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison

Open access
Ratcliff, A, Siswantoro, H, Kenangalem, E, Maristela, R, Wuwung, RM, Laihad, F, Ebsworth, EP, Anstey, NM, Tjitra, E, Price, RN·2007·The Lancet

Abstract

Summary Background The burden of Plasmodium vivax infections has been underappreciated, especially in southeast Asia where chloroquine resistant strains have emerged. Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by multidrug-resistant P falciparum and P vivax. Methods 774 patients in southern Papua, Indonesia, with slide-confirmed malaria were randomly assigned to receive either artemether-lumefantrine or dihydroartemisinin-piperaquine and followed up for at least 42 days. The primary endpoint was the overall cumulative risk of parasitological failure at day 42 with a modified intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, trial number 00157833. Findings Of the 754 evaluable patients enrolled, 466 had infections with P falciparum, 175 with P vivax, and 113 with a mixture of both species. The overall risk of failure at day 42 was 43% (95% CI 38–48) for artemether-lumefantrine and 19% (14–23) for dihydroartemisinin-piperaquine (hazard ratio=3·0, 95% CI 2·2–4·1, p<0·0001). After correcting for reinfections, the risk of recrudescence of P falciparum was 4·4% (2·6–6·2) with no difference between regimens. Recurrence of vivax occurred in 38% (33–44) of patients given artemether-lumefantrine compared with 10% (6·9–14·0) given dihydroartemisinin-piperaquine (p<0·0001). At the end of the study, patients receiving dihydroartemisinin-piperaquine were 2·0 times (1·2–3·6) less likely to be anaemic and 6·6 times (2·8–16) less likely to carry vivax gametocytes than were those given artemether-lumefantrine. Interpretation Both dihydroartemisinin-piperaquine and artemether-lumefantrine were safe and effective for the treatment of multidrug-resistant uncomplicated malaria. However, dihydroartemisinin-piperaquine provided greater post-treatment prophylaxis than did artemether-lumefantrine, reducing P falciparum reinfections and P vivax recurrences, the clinical public-health importance of which should not be ignored.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(07)60160-3

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 271

Metadata

Authors
Ratcliff, A., Siswantoro, H., Kenangalem, E., Maristela, R., Wuwung, R., Laihad, F., Ebsworth, E., Anstey, N., Tjitra, E., & Price, R.
Venue
The Lancet
Publisher
Elsevier BV
Published
2007-03
Volume
369
Issue
9563
Pages
757-765
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2166357496
Cited by
271
References
30
FWCI
32.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. https://app.cochat.ai/papers/10.1016/s0140-6736(07)60160-3
The paper
Ratcliff, A., Siswantoro, H., Kenangalem, E., Maristela, R., Wuwung, R., Laihad, F., Ebsworth, E., Anstey, N., Tjitra, E., & Price, R. (2007). Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. The Lancet. https://doi.org/10.1016/s0140-6736(07)60160-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.